To determine the impact oral Acetazolamide in changing short time intraocular pressure (IOP) fluctuation in intra vitreous bevacizumab injection

A comparison changing short time intraocular pressure (IOP) fluctuation in intravitreal bevacizumab injection with and without acetazolamide oral drug in amir almomenin hospital, A clinical trial study

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210408050895N1

Enrollment

340

Registered

2021-06-20

Start date

2021-06-20

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

all of the patients with a eye disease need to intravitreous bevacizumab injection.

Interventions

Intervention 1: Intervention group: Patients in Intervention groups at first measuring intraocular pressure with Tonometry slit lamp. Then receiving oral Acetazolamide 250mg , 30 minutes before intrav

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: all of the patients with a eye disease need to intra vitreous bevacizumab injection in amiralmomnin hospital

Exclusion criteria

Exclusion criteria: patients with a history of glaucoma ¸ glaucoma surgery scleral buckle ( SB) deep vitrectomy (Vitx) iris neovascularization (NI) history of anti-glaucoma drug

Design outcomes

Primary

Measure	Time frame
Intraocular pressure. Timepoint: half an hour before injecting bevacizumab in vitrous and three hours after injection. Method of measurement: Tonometer Asylum Lamp.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Behboudi

Rasht University of Medical Sciences

behboudi_dr@yahoo.com+98 13 3323 6886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026